Store
Genetic Testing Markets for Epilepsy, Autism, Alzheimer’s and Other Neurologic Conditions
Publication Date: January 4, 2021
Tags: Diagnostic Instruments, Genetic Diseases, Neurological Diseases, Next-Generation Sequencing (NGS), Next-Generation Sequencing (NGS) Systems, Sequencing, Sequencing Technologies
Pages: 40
SKU: 21-045
The genetic involvement in the pathogenesis of neurological diseases is profound, with central nervous system disorders accounting for about 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases. Neurological diseases, especially brain diseases, represent the final frontier in medical discovery. Advances in testing, such as next-generation sequencing (NGS), have been instrumental in identifying genetic causes for neurological conditions, driving significant progress in this field.
Kalorama Information’s Genetic Testing Markets for Epilepsy, Autism, Alzheimer’s and Other Neurologic Conditions focuses on the neurological segments of the inherited/genetic disease testing market. This report covers autism, Alzheimer’s disease, and other neurological diseases, highlighting the transformative impact of NGS technologies.
Key Features of the Report:
- Market Overview:
- Comprehensive analysis of the genetic testing market for neurological conditions.
- Examination of market trends, technological advancements, and key drivers.
- Selected Companies and Products:
- Detailed profiles of leading companies and their product offerings in the neurological genetic testing market.
- Market Forecast (2020-2025):
- Genetic neurological testing market projections in dollar values.
- Segmentation by disease type (Autism, Alzheimer’s, and other Neurological Diseases).
- Impact of COVID-19:
- Analysis of how the COVID-19 pandemic has influenced the neurological genetic testing market.
In-Depth Analysis:
- Genetic Testing by Disease Type (2020-2025):
- Autism
- Alzheimer’s Disease
- Other Neurological Diseases
- Next-Generation Sequencing (NGS):
- Overview of NGS capabilities and its role in genetic testing for neurological conditions.
- Insights into the affordability and efficiency of sequencing technologies, including single genes, panels, exomes, and other methods.
Competitive Landscape:
- Companies in the Market:
- Profiles of key players in the genetic testing market for neurological conditions.
- Analysis of their strategies, product innovations, and market positioning.
Table: Genetic Testing, by Disease Type, 2020-2025 ($ millions)
| Disease Type | 2020 | 2025 | CAGR |
| Autism | $XX Millions | $XX Millions | XX% |
| Alzheimer’s disease | $XX Millions | $XX Millions | XX% |
| Epilepsy | $XX Millions | $XX Millions | XX% |
| Other Neurological diseases (ALS, Parkinson’s, etc) | $XX Millions | $XX Millions | XX% |
| Total | $XX Millions | $XX Millions | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
MARKET OVERVIEW AND POTENTIAL
- Table 1-1: Genetic Neurological Testing 2020-2025 (in $ millions)
COVID-19 IMPACT
CHAPTER 2: INTRODUCTION
OVERVIEW
Autism
Alzheimer’s Disease
Other Neurological Diseases
Types of Testing
Limitations in Exome Sequencing
Costs of Exome Sequencing
Areas of Difficulty for NGS to Penetrate Market
Role of FISH/ISH
De Novo Mutations Not Excluded
CHAPTER 3: PRODUCTS AND MARKET POTENTIAL
GENETIC TESTING FOR AUTISM
GENETIC TESTING FOR ALZHEIMER’S DISEASE
GENETIC TESTING FOR OTHER SELECT NEUROLOGICAL DISEASES
- Table 3-1: Selected Companies and Products in the Neurological Genetic Testing Market
MARKET REVENUE AND FORECAST
- Table 3-2: Genetic Neurological Testing 2020-2025 (in $ millions)
- Table 3-3: Genetic Testing by Disease Type Autism, Alzheimer’s and other Neurological Diseases 2020-2025 (in $ millions)
CHAPTER 4: MARKET PARTICIPANTS
AMBRY GENETICS
- Table 4-1: Ambry Genetics Corporate Summary
- Company Information
ARUP LABORATORIES
- Table 4-2: ARUP Laboratories Corporate Details
- Company Information
ASURAGEN
- Table 4-3: Asuragen Corporate Summary
- Company Information
ATHENA DIAGNOSTICS, INC.
- Table 4-4: Athena Diagnostics Corporate Summary
- Company Information
BLUEPRINT GENETICS
- Table 4-5: Blueprint Genetics Corporate Summary
- Company Information
CENTOGENE AG
- Table 4-6: Centogene Corporate Summary
- Company Information
CYTOX GROUP LIMITED
- Table 4-7: Cytox Corporate Summary
- Company Information
FULGENT GENETICS
- Table 4-8: Fulgent Genetics Corporate Summary
- Company Information
GENEDX
- Table 4-9: GeneDx Corporate Summary
- Company Information
ILLUMINA
- Table 4-10: Illumina Corporate Summary
- Company Information
INVITAE
- Table 4-11: Invitae Corporate Summary
- Company Information
LABORATORY CORPORATION OF AMERICA
- Table 4-12: LabCorp Corporate Summary
- Company Information
LINEAGEN
- Table 4-13: Lineagen Corporate Summary
- Company Information
PERKINELMER, INC.
- Table 4-14: PerkinElmer Corporate Summary
- Company Information
QUEST
- Table 4-15: Quest Corporate Summary
- Company Information
THERMO FISHER SCIENTIFIC
- Table 4-16: Thermo Fisher Scientific Corporate Summary
- Company Information
Related products
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
Price range: $3,000.00 through $4,500.00
Clinical Laboratory Services Market, 8th Edition
May 18, 2023
Laboratories are the workhorse of diagnostic services for the IVD market. These laboratories play a vital role in providing analysis of a wide range of disorders and diseases including pathology, immunology, cholesterol testing, allergy testing, urinalysis, genetic testing and many more. Kalorama Information’s Clinical Laboratory Services Market, 8th Edition is your comprehensive resource for insights…
Price range: $4,000.00 through $6,000.00
Cell and Gene Therapy Deals Analysis, 2021-2024
June 3, 2024
Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…
Price range: $6,300.00 through $9,450.00
